MAPK1 and melanoma: Following drug removal from dabrafenib- and trametinib-resistant melanoma cells or EGFRi-resistant lung cancer cells, the Mek1/Erk2 rebound activity drives the JunB and Fra-1 accumulation, which triggers proliferative arrest and/or cell death [81].